Erratum to: Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration (Invest Ophthalmol Vis Sci., (2017), 58, (1893-1898), 10.1167/iovs.16-20786);Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 58, Issue 3, 2017, Pages 1893-1898

  Wen, Joanne C ^a,b   Reina Torres, Ester ^c   Sherwood, Joseph M ^c   Challa, Pratap ^b   Liu, Katy C ^b   Li, Guorong ^b   Chang, Jason Y H ^c   Cousins, Scott W ^b   Schuman, Stefanie G ^b   Mettu, Priyatham S ^b   Stamer, W Daniel ^b   Overby, Darryl R ^c   Allingham, R Rand ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY EYE CENTER   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti VEGF; Aqueous outflow facility; Intraocular pressure; Ocular hypertension

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; AQUEOUS HUMOR OUTFLOW; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; AQUEOUS HUMOR; CHOROIDAL NEOVASCULARIZATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AQUEOUS HUMOR; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; TIME FACTORS; TONOMETRY, OCULAR; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

EID: 85016565230     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-20786a     Document Type: Erratum

References (37)

1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
2. Martin DF, Maguire MG, Fine SL, et al.; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med. 2006;355:1419–1431.
4. Williams GA. IVT injections: health policy implications. Rev Ophthalmol. 2014;21:62–64. Available at: https://www. reviewofophthalmology.com/article/ivt-injections-health-policy-implications. Accessed August 10, 2016.
5. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes follow- ing intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181–185.
6. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–934.e1.
7. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26:105–110.
8. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefe’s Arch Clin Exp Ophthalmol. 2008;246:955–958.
9. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31:1028–1035.
10. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111–1114.
11. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013; 33:179–187.
12. Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol. 2011;31:211–213.
13. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol. 2012;250:1435–1440.
14. Segal O, Ferencz JR, Cohen P, Nemet AY, Nesher R. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Israel Med Ass J. 2013;15:352–355.
15. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28–29.
16. Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: what is the evidence? Retina. 2015;35:841–858.
17. Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52:1023–1034.
18. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158:319–327.e2.
19. Wen JC, Cousins SW, Schuman SG, Allingham RR. Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections. Retina. 2016.
20. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19:437–441.
21. Fujimoto T, Inoue T, Maki K, Inoue-Mochita M, Tanihara H. Vascular endothelial growth factor-a increases the aqueous humor outflow facility. PLoS One. 2016;11:e0161332.
22. Reina-Torres E, Wen JC, Liu K, et al. VEGF as a paracrine regulator of conventional outflow facility. 2017;58:1899–1908.
23. Selvadurai D, Hodge D, Sit AJ. Aqueous humor outflow facility by tonography does not change with body position. Invest Ophthalmol Vis Sci. 2010;51:1453–1457.
24. Williams AL, Gatla S, Leiby BE, et al. The value of intraocular pressure asymmetry in diagnosing glaucoma. J Glaucoma. 2013;22:215–218.
25. Becker B. The decline in aqueous secretion and outflow facility with age. Am J Ophthalmol. 1958;46:731–736.
26. Nau CB, Malihi M, McLaren JW, Hodge DO, Sit AJ. Circadian variation of aqueous humor dynamics in older healthy adults. Invest Ophthalmol Vis Sci. 2013;54:7623–7629.
27. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology. 2014; 121:1102–1108.
28. Kim YJ, Sung KR, Lee KS, et al. Long-term effects of multiple intravitreal anti-vascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol. 2014;157:1265–1271.
29. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32:1295–1301.
30. Drance SM. The uniocular therapeutic trial in the management of elevated intraocular pressure. Surv Ophthalmol. 1980;25:203–205.
31. King AJ, Rotchford AP. Validity of the monocular trial of intraocular pressure-lowering at different time points in patients starting topical glaucoma medication. JAMA Ophthalmol. 2016;134:742–747.
32. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731–1739.
33. Gal-Or O, Dotan A, Dachbash M, et al. Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. Exp Eye Res. 2016;145:412–416.
34. Hanhart J, Tiosano L, Averbukh E, et al. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye. 2014;28:646–653.
35. Kee C, Moon SH. Effect of cataract extraction and posterior chamber lens implantation on outflow facility and its response to pilocarpine in Korean subjects. Br J Ophthalmol. 2000;84:987–989.
36. Meyer MA, Savitt ML, Kopitas E. The effect of phacoemulsi-fication on aqueous outflow facility. Ophthalmology. 1997; 104:1221–1227.
37. Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol. 2010;21:118–122.